Bank Of New York Mellon Corp Prometheus Biosciences, Inc. Transaction History

Bank Of New York Mellon Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$36.06 - $117.21 $5.45 Million - $17.7 Million	151,202 New	151,202 $16.6 Million
Q3 2022 Nov 14, 2022	BUY	$28.17 - $59.01 $756,420 - $1.58 Million	26,852 Added 27.73%	123,697 $7.3 Million
Q2 2022 Aug 15, 2022	SELL	$22.39 - $38.94 $711,576 - $1.24 Million	-31,781 Reduced 24.71%	96,845 $2.74 Million
Q1 2022 May 11, 2022	BUY	$30.13 - $50.0 $356,859 - $592,200	11,844 Added 10.14%	128,626 $4.86 Million
Q4 2021 Feb 11, 2022	BUY	$22.28 - $39.54 $1.85 Million - $3.28 Million	82,928 Added 244.96%	116,782 $4.62 Million
Q3 2021 Nov 12, 2021	BUY	$20.89 - $26.96 $51,180 - $66,052	2,450 Added 7.8%	33,854 $803,000
Q2 2021 Aug 11, 2021	BUY	$16.8 - $29.65 $527,587 - $931,128	31,404 New	31,404 $771,000

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.